CONSHOHOCKEN, PA and KING OF PRUSSIA, PA — Clinical trial technology leaders Suvoda and Greenphire have announced plans to merge, a move poised to redefine the patient and site experience in clinical trials. The merger will combine the strengths of both companies to offer a comprehensive platform aimed at improving access, engagement, and efficiency for patients, sites, and sponsors alike.
The combined entity will deliver an end-to-end clinical trial management solution, encompassing randomization and trial supply management, eConsent, eCOA, patient and site payments, study budgeting, as well as travel and logistics. This unified digital approach seeks to streamline workflows, enhance the user experience, and ultimately accelerate the delivery of medicines to patients in need.
“Suvoda and Greenphire are both mission-driven businesses, focused on easing sponsor, site, and patient burden in clinical trials,” said Jagath Wanninayake, Founder and CEO of Suvoda. “Combined, we’ll continue to deliver with the same excellence and service our customers expect, while accelerating the pace of product innovation in the most urgent moments of the most urgent trials.”
Leadership and Strategic Investments
Jagath Wanninayake will serve as CEO of the merged company, with Jim Murphy, Greenphire’s CEO, overseeing Greenphire operations through the close of the transaction in Q2 2025 and continuing as an advisor for the rest of the year to ensure a seamless transition. A leadership team consisting of representatives from both organizations will oversee operations, signaling a collaborative effort to advance mutual goals.
The merger is backed by Thoma Bravo, a prominent software investment firm that will act as the lead strategic investor. Bain Capital Tech Opportunities will also provide significant minority investment in the combined entity, strengthening its financial resources and capacity for innovation.
According to Hudson Smith, Partner at Thoma Bravo, “The combination of Suvoda and Greenphire, two leaders in clinical trial technology, will create a new company with significant scale, a unique set of complementary product offerings, and a highly skilled management team with an impressive track record of success and history of high growth.”
Enhancing the Clinical Trial Ecosystem
The merger comes at a critical moment as pharmaceutical companies increasingly rely on advanced technology to manage the growing complexity of clinical trials. By combining their expertise, Suvoda and Greenphire aim to simplify workflows and improve engagement across the board.
“The merger will enable us to even better serve all clinical trial stakeholders as we work with our new colleagues to redefine the site and patient experience,” said Jim Murphy. “By putting these two industry leaders together, our organization will be able to offer you the unprecedented ability to partner with one singular solution provider.”
This landmark agreement aim to not only streamline the clinical trial process, but also enhance the overall ecosystem by providing a seamless and comprehensive solution for site and patient engagement.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.